Heart attacks could be reduced by rethinking the way we prescribe statins

Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications. The findings, which are published online in Circulation, the journal of the American Heart Association, could improve prevention of heart disease, especially in younger people.

"Our study is changing the way we think about prescribing statins; we should not only be considering who is at risk of heart disease but, more importantly, who would benefit from these medications," says study-lead author, Dr. George Thanassoulis, who is the director of Preventive and Genomic Cardiology at the MUHC and an associate professor in Medicine at McGill University. "For example, younger patients who have high cholesterol, are frequently considered too young to be at risk for heart attack in the short term, but our analysis shows that they would benefit from treatment, even in the short term, and therefore should be eligible for statin treatment."

The research team performed their modelling study using data from 2,134 participants from the National Health and Nutrition Examination Survey - a nationally-representative US cohort, between 2005 and 2010, representing 71.8 million Americans potentially eligible for statins. Two approaches for statin eligibility were compared: a ten-year risk based approach, currently in use, and an individualized benefit approach. The latter method of determining who should receive statins was found to produce greater eligibility.

"Using a benefit-based approach, we identified 9.5 million lower-risk Americans not currently eligible for statin treatment, who had the same or greater expected benefit from statins as higher-risk individuals," explains Dr. Thanassoulis. "These individuals were lower-risk because they were younger but they also had higher levels of low-density lipoprotein cholesterol which we have known to be an important cause of heart disease. Targeting statin treatment to this group would prevent an additional 266,000 heart attacks and strokes over 10 years,"

"This strategy will transform cardiovascular prevention for the better," adds study's co-author, Dr. Allan Sniderman, MUHC cardiologist and full professor in Medicine at McGill University. "For too many, the present approach starts too late; an earlier start will multiply the lives saved."

Dr. Thanassoulis and collaborators are now developing a Web interface to extend the use of this calculation model to physicians. Researchers hope this new way will help develop guideline recommendations that better identify individuals who meaningfully benefit from statin therapy.

This study was funded by the Fonds de recherche du Québec - Santé and by the Doggone Foundation. The paper was coauthored by George Thanassoulis and Allan D. Sniderman (Research Institute of the McGill University Health Centre and McGill University, Montreal, QC, Canada); Ken Williams (KenAnco Biostatistics and University of Texas Health Science Center, San Antonio, TX); Kathleen Kimler Altobelli (KenAnco Biostatistics, San Antonio, TX), Michael J. Pencina (Duke Clinical Research Institute, Durham, NC), Christopher P. Cannon (Harvard Clinical Research Institute and Brigham and Women's Hospital, Boston, MA).

Most Popular Now

Roche launches imCORE, a global network of cancer …

Roche (SIX: RO, ROG; OTCQX: RHHBY) has launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the...

Read more

15th Annual eyeforpharma Philadelphia 2017

20 - 21 April 2017, Philadelphia, USA. It's eyeforpharma Philadelphia's 15th year; already the largest, most senior and most influential forum for commercial pharma exec...

Read more

Merck wins R&D 100 Award for top invention

Merck, a leading science and technology company, received a prestigious R&D 100 Award for its Sanger Arrayed Lentiviral CRISPR Libraries - the first of its kind CRISPR li...

Read more

Benzodiazepine and related drug use increases hip …

The use of benzodiazepines and related drugs increases the risk of hip fracture by 43% in persons with Alzheimer's disease, according to a new study from the University o...

Read more

Among antidementia drugs, memantine is associated …

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of...

Read more

World of viruses uncovered

A groundbreaking study of the virosphere of the most populous animals - those without backbones such as insects, spiders and worms and that live around our houses - has u...

Read more

Boehringer Ingelheim and China Southeast Universit…

Boehringer Ingelheim and China Southeast University Institute of Life Sciences have announced the start of a joint research project to develop new treatment approaches fo...

Read more

Smart patch releases blood thinners as needed

An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occur...

Read more

Novartis acquires Selexys Pharmaceuticals Corporat…

Novartis today announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammator...

Read more

Novo Nordisk expands programme to reach 20,000 chi…

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children wi...

Read more

IBM and Pfizer to accelerate immuno-oncology resea…

IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) have announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's resea...

Read more

Greater efforts are needed to encourage patients t…

In a review of published studies addressing patients' perceptions and factors influencing their reporting of adverse drug reactions, most patients were not aware of repor...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]